The cancellation of a pilot program, which would have been mandatory for all providers and suppliers that furnish and bill for Medicare Part B drugs, was welcome news for physicians.
Numerous organizations applauded the Centers for Medicare & Medicaid Services' decision to cancel its proposed five-year Part B payment model demonstration. The model would have created incentives for patients and physicians to select lower-cost, high-performing drugs that are administered at medical facilities.
The Medical Group Management Association (MGMA) said the proposal would not have tackled the root cause of growing Part B drug costs, which it said are set by manufacturers. “Our primary concern was it would force physician practices to either write off losses from below-cost drug reimbursements to physicians or send patients to more expensive hospital outpatient departments for life-saving treatments such as chemotherapy,” said MGMA’s president and CEO Halee Fisher-Wright, M.D.
Of particular concern of opponents was the impact on cancer patients. The Community Oncology Alliance, a non-profit organization that advocates for community oncology practices, also welcomed the news. “Cancer patients and their providers across the country can breathe a sigh of relief now that the Part B experiment on cancer care is finally dead,” said Ted Okon, executive director, in an announcement.
Rheumatologists were also vocal opponents of the demonstration because of concerns that it would negatively and disproportionately impact their patients’ ability to access biologic therapies. The American College of Rheumatology said the decision is good news for rheumatology patients who rely on Medicare Part B to access life-saving biologic therapies.
“For older Americans living with painful and debilitating diseases like rheumatoid arthritis, lupus, spondyloarthritis and psoriat
The American Medical Association also hailed CMS’ decision to scrap the demonstration entirely, saying it would hurt patient care.